Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.

Mueller, Kelly L.
Madden, Julie M.
Zoratti, Gina L.
Kuperwasser, Charlotte.
List, Karin.
Boerner, Julie L.
2012

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown clinical efficacy in lung, colon, and pancreatic cancers. In lung cancer, resistance to EGFR TKIs correlates with amplification of the hepatocyte growth factor (HGF) receptor tyrosine kinase Met. Breast cancers do not respond to EGFR TKIs, even though EGFR is overexpressed. This intrinsic resistance ... read more

Permanent URL
http://hdl.handle.net/10427/010552
Original publication
Mueller, Kelly, Julie M. Madden, Gina L. Zoratti, Charlotte Kuperwasser, Karin List, and Julie L. Boerner. "Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met." Breast Cancer Research 14, no. 6 (8, 2012): 1-11.
ID: tufts:19570
To Cite: DCA Citation Guide
Usage: Detailed Rights